Despite the increasing acceptance and legalization of cannabis for medical and the legalization of recreational marijuana across several states in the US, there is still a significant difference in the way cannabis-related offenses are treated at the federal level. The Biden administration's stance on cannabis policy, specifically its classification as a Schedule I drug under the Controlled Substances Act, creates a rift between state and federal laws. This inconsistency leads to unfair penalties, preventing researchers from exploring the medicinal potential through pharmaceutical trials.
To resolve the issue, a significant overhaul of federal cannabis laws is necessary to match the changing landscape of cannabis legalization at the state level. The
Associated Press reports that the Biden administration could consider reclassifying cannabis to a less restrictive category under the Controlled Substances Act, acknowledging its potential medical benefits and the changing attitudes toward its use. Additionally, federal legislation could be introduced to decriminalize marijuana possession and expunge prior cannabis-related convictions. This would reduce the burden on the criminal justice system and promote a more equitable approach to cannabis regulation across the country.
A recent book,
Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases (ISBN: 9781668456521), presents the findings from clinical and basic medical scientists who are studying the cellular and molecular mechanisms of cannabinoid-mediated inhibition of innate and adaptive immune responses. It also looks at the mobilization of myeloid-derived immunosuppressive cells, enhancement of neuroprotection, facilitation of oligodendrocyte survival, promotion of CNS progenitor cell differentiation to support regeneration and remyelination, arrest of tumor cell proliferation, decrease in tumor cell adhesion, disruption of tumor angiogenesis, inhibition of endothelial cells, and prevention of cancer metastasis by inhibition of cell migration. The book provides the necessary knowledge to educate people on the uses and effectiveness of alternative medicine.
About IGI Global – Publishing Tomorrow’s Research Today
Founded in 1988 and headquartered in Hershey, Pennsylvania, USA, IGI Global is a leading medium-sized independent international academic publisher of cutting-edge, high-quality, peer-reviewed scholarly reference publications in the three major academic subject areas of
Business & Management,
Scientific, Technical, & Medical (STM), and
Education. With a commitment to facilitating the discovery of pioneering scientific research, this publishing house has empowered over 200,000+ expert researchers from leading institutions globally to bring advanced reference books and scholarly journals to the research community. IGI Global’s Open Access Journal Program includes nearly 200+ active fully open access journals and at present, IGI Global is one of the largest 100% open access journal publishers in the world. Through traditional and open access publishing workflows, IGI Global’s unique, swift, and agile proprietary processes (books release in roughly 6-9 months from start to finish) ensures that
tomorrow’s researchis published today.
Learn more about IGI Global
here.